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Beta-adrenergic blocking agents known as 
beta blockers are widely used in clinical prac-
tice to treat several cardiovascular disorders 
such as hypertension and high blood pressure 
in general. They are also used as cardiopro-
tective agents in post myocardial infarction, 
for the treatment of cardiac arrhythmias 
and were reported to be beneficial in treat-
ing migraine. Recently, they were shown to 
be efficacious in treating patients with several 
types of congenital long QT syndromes and 
in patient with catecholaminergic polymor-
phic ventricular tachycardia.
They mainly act by antagonizing the 
effects of norepinephrine released from 
sympathetic nerve endings on beta adren-
oceptors. A direct interaction with ion 
channels in addition to the beta blocking 
property is now becoming more and more 
accepted in the scientific community. 
Propranolol is the beta blocker prototype, 
it is commonly used as racemic mixture 
with equal concentrations of R-(+)- and 
S-(−)-enantiomers. Although, they have 
been classified as class II antiarrhythmic 
drugs by Vaughan Williams the molecular 
mechanisms by which they act is not fully 
elucidated. On the other hand, their ben-
eficial effect in preventing migraine is not 
well understood.
Earlier electrophysiological studies have 
reported the effects of propranolol on heart 
rate and conduction properties in frog 
auricular fibers, rat, and canine ventricu-
lar myocytes. Recent data have shown that 
beta blockers could modulate Na
v
1.5, the 
cardiac voltage-gated sodium channels, but 
the effect on the expressed brain sodium 
channels was not envisaged. In the paper by 
Wang et al., the authors studied the effect 
of propanol on heterologously expressed 
recombinant human cardiac (Na
v
1.5) and 
the three brain (Na
v
1.1, Na
v
1.2, and Na
v
1.3) 
sodium channels using whole-cell patch 
clamp recordings.
Previous work from the author’s group 
showed that racemic propranolol and 
R-(+)-propranolol block Na
v
1.5 channels 
(Wang et al., 2008). In this paper the authors 
extended their study to evaluate the molec-
ular mechanism of the reported block. Both 
R-(+) and S-(−) propranolol block Na
v
1.5 
sodium channels in tonic and phasic (use-
dependent or frequency-dependent) man-
ner with similar affinities. However, nadolol 
a non-selective beta blocker and metopro-
lol a selective beta 1 blocker did not induce 
any tonic or phasic block, suggesting that 
the sodium  channel block property is not 
common to all beta blockers. More detailed 
biophysical studies from the authors 
revealed that that R-(+)-propranolol 
exhibits biophysical effects on Na
v
1.5 that 
are similar but not identical to lidocaine, 
the class 1 antiarrhythmic drug prototype. 
That R-(+)-propranolol acts as a typical 
local anesthetic and class 1 antiarrhyth-
mics on sodium channels by interacting 
with specific residues in the DIV-S6 seg-
ment, including the phenylalanine-1760, 
known to play a central role in drug binding 
(Ragsdale et al., 1994) and therefore shares 
this property with established antiarrhyth-
mic drugs. Finally, further detailed bio-
physical study from the authors showed 
that the brain sodium channels (Na
v
1.1, 
Na
v
1.2, and Na
v
1.3) exhibit less sensitiv-
ity to R-(+)-propranolol than the Na
v
1.5 
channels. Since the phenylalanine-1760 is 
a conserved residue in all sodium channels, 
including brain sodium channels, studies to 
elucidate the basis of this reduced affinity 
at molecular level are warranted.
These data reported by Wang et al., in 
this issue of Frontiers in Pharmacology of 
Ion Channel and Channelopathies, will 
pave the path toward a more understand-
ing of the effect of beta blockers on sodium 
 channels, a widely used class of drugs.
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